Medcura developed novel LifeGel™ Absorbable Surgical Hemostat to control bleeding during surgical procedures.
LifeGel™ is the first and only haemostatic agent indicated for use in surgical procedures (except in ophthalmic and urological) as an adjunctive haemostatic device where control of minimal, mild, and moderate bleeding by traditional procedures are ineffective or innappropriate. LifeGel™ consisting no-swell properties, can be used in surgical procedures where swelling is not tolerated.
Other haemostatic agents swell after application. It is observed that haemostatic agents when used in confined spaces like the spinal canal where up to 60% of these products are applied, resulted causing nerve compression leading to events including paralysis. Apart from various other haemostatic agents, LifeGel contains no human or animal proteins, including thrombin, and does not require no pre-mixing, preparation or cold chain storage.
Ready to use LifeGel helps to lower costly delays, risks and complications related to uncontrolled bleeding and reduce wastage of expensive haemostatic materials in the operating room. These features, along with the platform's disruptive cost advantage, makes LifeGel an upcoming standard of care for surgical bleeding management.
U.S. Food and Drug Administration (FDA) grants the Breakthrough Device Designation for LifeGel™ Absorbable Surgical Hemostat.
